Related Experiment Video

Updated: Sep 30, 2026

Neo-Islet Formation in Liver of Diabetic Mice by Helper-dependent Adenoviral Vector-Mediated Gene Transfer
16:59

Neo-Islet Formation in Liver of Diabetic Mice by Helper-dependent Adenoviral Vector-Mediated Gene Transfer

Published on: October 10, 2012

PTP1B antisense oligonucleotide lowers PTP1B protein, normalizes blood glucose, and improves insulin sensitivity in

Bradley A Zinker1, Cristina M Rondinone, James M Trevillyan

  • 1Abbott Laboratories, 100 Abbott Park Road, Abbott Park, IL 60064-3500, USA. bradley.zinker@abbott.com

Proceedings of the National Academy of Sciences of the United States of America
|August 10, 2002
PubMed

Insights

Inhibiting protein-tyrosine phosphatase 1B (PTP1B) using antisense oligonucleotides improved glucose control and insulin sensitivity in diabetic mice. This suggests PTP1B is a potential therapeutic target for type 2 diabetes.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Endocrinology

Background:

  • Protein-tyrosine phosphatase 1B (PTP1B) is implicated in insulin resistance.
  • Dysregulation of PTP1B activity contributes to the pathophysiology of type 2 diabetes.

Purpose of the Study:

  • To investigate the therapeutic potential of PTP1B inhibition in a mouse model of type 2 diabetes.
  • To elucidate the molecular mechanisms underlying PTP1B's role in insulin signaling and glucose metabolism.

Main Methods:

  • Utilized antisense oligonucleotide (ASO) therapy to reduce PTP1B expression in ob/ob and db/db mice.
  • Assessed metabolic parameters including plasma glucose, HbA(1C), and insulin sensitivity.
  • Analyzed PTP1B expression and insulin signaling pathway components in liver, fat, and skeletal muscle.

Main Results:

  • PTP1B ASO treatment normalized glucose levels, reduced HbA(1C), and improved insulin sensitivity.
  • Decreased PTP1B expression in liver and fat led to enhanced insulin signaling, including increased Akt phosphorylation.
  • Down-regulation of key gluconeogenic enzymes in the liver was observed.

Conclusions:

  • PTP1B plays a critical role in modulating insulin signaling in hepatic and adipose tissues.
  • Targeting PTP1B with therapeutic agents represents a promising strategy for managing type 2 diabetes.
  • Further research into PTP1B inhibitors could yield novel treatments for metabolic disorders.

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Cell Specific Gene Expression01:58

Cell Specific Gene Expression

Multicellular organisms contain a variety of structurally and functionally distinct cell types, but the DNA in all the cells originated from the same parent cells. The differences in the cells can be attributed to the differential gene expression. Liver cells, whose functions include detoxification of blood, production of bile to metabolize fats, and synthesis of proteins essential for metabolism, must express a specific set of genes to perform their functions. Gene expression also varies with...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...